INTRODUCTION {#s1}
============

Whole-exome sequencing (WES) provides a comprehensive strategy to identify pathogenic genetic variants in patients with developmental abnormalities ([@TANAKAMCS000356C37]; [@TANAKAMCS000356C39], [@TANAKAMCS000356C40]). The 5q31.3 microdeletion syndrome is associated with hypotonia, feeding difficulties, severe developmental delay, and epilepsy. Genomic 5q31.3 deletions range in size from 101 kb to 5 Mb and include the purine-rich element binding protein A (*PURA*), a candidate gene for the developmental manifestations ([@TANAKAMCS000356C35]; [@TANAKAMCS000356C12]; [@TANAKAMCS000356C1]). *PURA* is essential for normal brain development, synapse formation and proliferation of neurons, oligodendrocytes, and astrocytes in the central nervous system ([@TANAKAMCS000356C21]; [@TANAKAMCS000356C15]; [@TANAKAMCS000356C11]). Mutations in *PURA* have previously been associated with moderate to severe developmental delay, learning disability, hypotonia, neonatal respiratory issues, feeding difficulties, and seizures or "seizure-like" movements in 15 patients ([@TANAKAMCS000356C13]; [@TANAKAMCS000356C25]). Here we describe six unrelated patients with de novo mutations in *PURA* identified through WES associated with the consistent phenotype of hypotonia and developmental delay and frequently associated with seizures.

RESULTS {#s2}
=======

Clinical Presentation {#s2a}
---------------------

Six unrelated patients all share similar clinical features of hypotonia and developmental delay ([Table 1](#TANAKAMCS000356TB1){ref-type="table"}). The children range in age from 6 mo to 15 yr, and none of the children are functionally verbal. There is no history of regression in any of the children. Patient 1 had poor suck, bradycardia, and apnea during the neonatal period. "Seizure-like" activity was observed in two patients. One had "seizure-like" activity (twitching, stiffening, staring spells, collapsing) with a normal EEG, and a second developed myoclonic movements and possible gelastic seizures at 3 yr of age. One child has a history of infantile spasms. Vision has been variably and minimally impaired in five of the children. All have normal hearing. One child also has mild osteopenia and a history of fractures. There is no evidence of other significant medical problems or birth defects. Four of the children are dysmorphic with varying features ([Fig. 1](#TANAKAMCS000356F1){ref-type="fig"}). Two of the patients have only minor features such as epicanthal folds or highly arched palate, while two other patients have more significant findings such as dolichocephaly, hypertelorism, broad forehead, and persistent fetal pads. Height and weight are within the normal range. Head circumferences ranged from less than the 10th to the 97th percentile. Brain MRI demonstrates delayed myelination and nonspecific enlargement of the subarachnoid spaces, cortical sulci, and ventricular system in one patient, periventricular white matter changes reflective of a stroke in the second patient, periventricular leukomalacia in the third, and mild corpus callosum volume loss in the fourth. Three of the patients have constipation and one also has gastroesophageal reflux disease. All children had clinical WES as part of a trio analysis wherein the proband and both parents were sequenced. There was no known history of consanguinity in any of the families.

![Photographs of patients. (*A*,*B*) Patient 1. (*C*) Patient 2. (*D*,*E*) Patient 3. (*F*) Patient 4. (*G*,*H*) Patient 6. Patients 1 and 2 exhibit dolichocephaly and Patients 1--5 all have a broad forehead. Note hypertelorism and highly arched palate in Patient 1 and epicanthal folds in Patient 4.](TanakaMCS000356_F1){#TANAKAMCS000356F1}

###### 

Clinical features of patients with mutations in *PURA*

  Patient                     Age    Sex        Mutation         Hypotonia   Head circumference      Age at sitting         Age at walking             Verbal skills                                       Vision                                          Brian MRI                 EEG                                      Seizure
  ------------------------- ------- ----- --------------------- ----------- -------------------- ----------------------- -------------------- ------------------------------- ---------------------------------------------------------------- ---------------------------------- ---------- --------------------------------------------------------------------------
  1                          8 yr     M         c.563T\>C            Y           97th %ile                1 yr                   3 yr             One word approximations                                  Normal                                 Slightly delayed myelination      Normal                            "Seizure-like" activity
  p.Ile188Thr                                                                                                                                                                                                                                                                                
  2                          4 yr     M         c.768dupC            Y            Unknown                 1 yr            4 yr with a walker             Nonverbal                             Optic nerve pallor, esotropia                          White matter changes          Normal                                      None
  p.Ile257Hisfs\*37                                                                                                                                                                                                                                                                          
  3                          10 yr    F          c.1A\>T             Y           50th %ile                1 yr                   4 yr                    Nonverbal                                 Strabismus, esotropia                                     Normal                Unknown                      Myoclonic, possible gelatic seizures
  p.Met1?                                                                                                                                                                                                                                                                                    
  4                          6 mo     F      c.697_699delTTC         Y          5--10th %ile               N/A                   N/A                        N/A                                  Cortical visual impairment                       Periventricular leukomalacia      Normal                                      None
  p.Phe233del                                                                                                                                                                                                                                                                                
  5                          15 yr    F       c.4_8delGCGGA          Y         25--50th %ile             Unknown                 4 yr                    Nonverbal                                       Exotropia                              Mild corpus callosum volume loss   Abnormal                               Infantile spasms
  p.A1a2Profs\*197                                                                                                                                                                                                                                                                           
  6                          5 yr     F    302_310delCTCTCTCCA       Y           33rd %ile                5 yr               Not walking                 Nonverbal                                 Myopia and strabismus                                     Normal                 Normal                    Spasticity in foot and lower extremities
  p.Thre101_Ser103del                                                                                                                                                                                                                                                                        
  Hunt et al. \#1            4 yr     F      c.726_727delGT          Y          9--25th %ile              2 yr              Nonambulatory                Nonverbal             Nystagmus with preserved optokinetic reflex, dysconjugate gaze         Delayed myelination           Normal                            "Seizure-like" episodes
  p.Phe243Tyrfs\*50                                                                                                                                                                                                                                                                          
  Hunt et al. \#2            14 yr    F         c.847delG            N          \<0.4th %ile              1 yr                   2 yr          Sentences; limited vocabulary                               Normal                                            Normal                  N/A                                        None
  p.Glu283Argfs\*45                                                                                                                                                                                                                                                                          
  Hunt et al. \#3            12 yr    F         c.616A\>T            Y         75--91st %ile              1 yr                   1 yr            Short phrases, repetitive                                 Normal                                            Normal                Abnormal                           "Seizure-like" episodes
  p.Ile206Phe                                                                                                                                                                                                                                                                                
  Hunt et al. \#4            6 yr     F      c.697_699delTTC         Y           75th %ile        Cannot sit unassisted     Nonambulatory                Nonverbal              Early cortical visual impairment, eye movements dysconjugate          Delayed myelination          Abnormal      Infantile spasms, progressed to tonic, focal dyscognitive seizures
  p.Phe233del                                                                                                                                                                                                                                                                                
  Lalani et al. \#1          6 mo     M      c.812_814delTCT         Y           86th %ile        Cannot sit unassisted          N/A                        N/A                                            Normal                                            Normal                Abnormal   Infantile myoclonus, partial onset with secondary clonic generalization
  p.Phe271del                                                                                                                                                                                                                                                                                
  Lalani et al. \#2          7 mo     M      c.307_308delTC          Y           20th %ile        Cannot sit unassisted          N/A                        N/A                                   Intermittent exotrophia                          Dysmorphic corpus callosum        N/A                                        None
  p.Ser103Hisfs\*97                                                                                                                                                                                                                                                                          
  Lalani et al. \#3          10 mo    M         c.556C\>T            Y           73rd %ile        Cannot sit unassisted          N/A                        N/A                                            Normal                                            Normal                 Normal        "Seizure-like" episodes in the neonatal period, myoclonic jerks
  p.Gln186\*                                                                                                                                                                                                                                                                                 
  Lalani et al. \#4          1 yr     F         c.289A\>G            Y           65th %ile                10 mo             Nonambulatory                Nonverbal                                       Strabismus                                          Normal                  N/A                        Myoclonic jerks, exaggerated startle
  p.Lys97Glu                                                                                                                                                                                                                                                                                 
  Lalani et al. \#5          4 yr     F         c.299T\>C            Y           66th %ile                1 yr              Nonambulatory                Nonverbal                               Nystagmus, Brown syndrome                        Mild myelin maturation delay       N/A                  Single generalized tonic clonic seizure at 5 mo
  p.Leu100Pro                                                                                                                                                                                                                                                                                
  Lalani et al. \#6          2 yr     F         c.363C\>G            Y           91st %ile                1 yr              Non-ambulatory               Nonverbal                                         Normal                                   Absent septum pellucidum       Abnormal                               Myoclonic jerks
  p.Tyr121\*                                                                                                                                                                                                                                                                                 
  Lalani et al. \#7          2 yr     F         c.783C\>G            Y           76th %ile                1 yr              Non-ambulatory               Nonverbal                                   Left eye estropia                                       Normal                Abnormal         Seizure-like episode in the neonatal period, myoclonic jerks
  p.Tyr261\*                                                                                                                                                                                                                                                                                 
  Lalani et al. \#8          5 yr     F         c.470T\>A            Y           85th %ile        Cannot sit unassisted     Nonambulatory                Nonverbal                                 Nystagmus, strabismus                                     Normal                  N/A                                        None
  p.Mct157Lys                                                                                                                                                                                                                                                                                
  Lalani et al. \#9          12 yr    M         c.265G\>C            Y          \>97th %ile       Cannot sit unassisted     Nonambulatory                Nonverbal                                       Nystagmus                                      Hypomyelination            Abnormal               Myoclonic, generalized tonic and atonic seizures
  p.Ala89Pro                                                                                                                                                                                                                                                                                 
  Lalani et al. \#10         12 yr    F      c.263_265delTCG         Y           50th %ile                2 yr                   3 yr                    Nonverbal                                   Strabismus, myopia                                      Normal                Abnormal          Lennox-Gastaut syndrome, intractable generalized epilepsy
  p.Ile88_Ala89delins Thr                                                                                                                                                                                                                                                                    
  Lalani et al. \#11         15 yr    F         c.596G\>C            Y              N/A                  Unknown            Nonambulatory                Nonverbal                            Nystagmus, extremely farsighted                                 N/A                  Abnormal   Lennox-Gastaut syndrome, myoclonic drops, tonic clonic, startle seizures
  p.Arg199Pro                                                                                                                                                                                                                                                                                

MRI, magnetic resonance imaging; EEG, electroencephalogram.

Exome sequencing produced an average of ∼13 Gb of sequence per sample ([Table 2](#TANAKAMCS000356TB2){ref-type="table"}). The mean coverage of captured regions was ∼150× per sample with \>98% covered with at least 10× coverage, an average of 92% of base call quality of Q30 or greater, and an overall average mean quality score of \>Q36. Filtering of common SNPs (\>10% frequency present in 1000 Genomes database) resulted in ∼4500 variants per proband sample. In total, 232 genes (257 unique sequence changes) of interest were identified across the six families when considering all possible modes of inheritance. Evaluation of these 232 genes eliminated 231 genes lacking clinical overlap with the patients' phenotype, leaving one gene.

###### 

Sequencing results

  Patient   10× cov. (%)   Mean cov.   Yield (Gb)   Q30   MeanQ   Filtered vars   *PURA* mean CDS cov.   Var. total fam. cov.   Samples   Mean per-sample var. cov.
  --------- -------------- ----------- ------------ ----- ------- --------------- ---------------------- ---------------------- --------- ---------------------------
  1         98.57          122         14.6         88    34      4973            105                    491                    3         164
  2         98.79          166         12.5         94    36      4057            128                    721                    3         240
  3         98.61          165         11.6         95    37      4475            143                    63                     3         21
  4         98.71          201         14.6         88    35      4613            149                    811                    3         270
  5         98.45          155         11.1         93    36      4504            125                    41                     3         14
  6         97.22          122         12.3         91    36      5445            70                     244                    3         81
  Mean      98.39          155         13           92    36      4678            120                    395                    3         132

cov., coverage; CDS, coding sequence; var., variance; fam, family.

Novel de novo heterozygous variants in *PURA* were detected by WES and confirmed by Sanger sequencing in six affected children ([Table 1](#TANAKAMCS000356TB1){ref-type="table"} and [Fig. 2](#TANAKAMCS000356F2){ref-type="fig"}). The *PURA* p.Ile188Thr (c.563T\>C) mutation in Patient 1 represents a nonconservative amino acid substitution of a hydrophobic residue replaced by a polar residue. Amino acid isoleucine 188 is highly conserved throughout evolution ([Fig. 2B](#TANAKAMCS000356F2){ref-type="fig"}). The c.768dupC (p.Ile257Hisfs\*37) mutation in Patient 2 produces a frameshift starting with codon isoleucine 257 that changes this amino acid to a histidine residue and creates a premature termination codon that deletes the last 66 amino acids after the insertion of 36 novel amino acids. This mutation is predicted to cause a loss of normal protein function through protein truncation. In Patient 3, the de novo c.1A\>T (p.Met1?) mutation alters the initiator methionine codon (Met1). It is not known whether the loss of Met1 disrupts all protein translation from that allele or whether an abnormal protein is produced using an alternate Met start codon. The c.697_699delTTC (p.Phe233del) mutation in Patient 4 is an in-frame deletion, previously reported in a patient by [@TANAKAMCS000356C13]. The c.4_8delGCGGA (p.Ala2Profs\*197) mutation identified in Patient 5 causes a frameshift starting with codon alanine 2, changes this amino acid to a proline residue and creates a premature termination codon and replaces the last 321 residues with 196 different ones. This mutation is predicted to cause a loss of normal protein function through protein truncation. Patient 6 has a c.302_310delCTCTCTCCA (p.Thr101_Ser103del) in-frame deletion of three amino acids in the highly conserved Pur I domain. None of the de novo variants identified in these six patients were detected in the Database of Single Nucleotide Polymorphisms (dbSNP; <http://www.ncbi.nlm.nih.gov/SNP/>), 1000 Genomes (1000G; <http://www.1000genomes.org/>), Exome Aggregation Consortium (ExAc; <http://exac.broadinstitute.org>), or Exome Variant Server (ESP; <http://evs.gs.washington.edu/EVS/>). All six mutations are located in highly conserved regions and all except for the mutation of Patient 3 are predicted to be deleterious by SIFT (<http://sift.jcvi.org/>), CADD (<http://cadd.gs.washington.edu/>), and MutationTaster (<http://www.mutationtaster.org/>). The de novo c.1A\>T (p.Met1?) mutation in Patient 3 is presumed deleterious by CADD and Mutation Taster.

![Mutations in *PURA.* (*A*) Diagram of Purα with mutations identified in our patients in green. Previously identified mutations are in orange ([@TANAKAMCS000356C13]; [@TANAKAMCS000356C25]). Missense and in-frame deletion mutations are shown *below* the protein diagram and gene disrupting truncating mutations are shown *above*. (*B*) Sequence alignment of Ile188 in PUR II region illustrating conservation of amino acids at amino acid 188.](TanakaMCS000356_F2){#TANAKAMCS000356F2}

DISCUSSION {#s3}
==========

Six unrelated patients ranging in age from 6 mo to 15 yr with common clinical features of hypotonia and developmental delay were all found to have heterozygous de novo predicted deleterious rare or novel variants in *PURA*, identified through WES ([Table 1](#TANAKAMCS000356TB1){ref-type="table"}). *PURA* is the leading candidate gene responsible for the developmental phenotype in the 5q31.3 microdeletion syndrome ([@TANAKAMCS000356C1]; [@TANAKAMCS000356C13]; [@TANAKAMCS000356C25]). Two papers recently reported de novo mutations in *PURA* in 15 individuals with developmental features equivalent to the 5q31.3 microdeletion syndrome ([@TANAKAMCS000356C13]; [@TANAKAMCS000356C25]). A separate large-scale WES study implicated 12 novel genes enriched for damaging de novo mutations with evidence for a role in developmental disorders ([@TANAKAMCS000356C5]). The analysis of the exomes of 1133 children with severe, undiagnosed developmental disorders and their parents identified *PURA* in three of the patients. We report six additional unrelated patients with de novo mutations in *PURA* to provide further evidence that *PURA* is largely, if not solely, responsible for the developmental delay, hypotonia, and seizures observed in the 5q31.3 microdeletion syndrome. Our additional patients expand the number and location of mutations in *PURA* and the associated phenotypes. Four of our patients had variants in the PUR domains, which are highly conserved throughout evolution ([Fig. 2](#TANAKAMCS000356F2){ref-type="fig"}).

*PURA* is located on 5q31.2 and is encoded by a single exon that encodes a highly conserved multifunctional protein, Purα. *PURA* is expressed ubiquitously, including the brain, muscle, heart, and blood. Purα is a member of the Pur family of nucleic acid binding proteins which consist of a glycine-rich flexible amino terminus, a central core region and a potential carboxy-terminal protein binding region. All human Pur proteins have three highly conserved sequence-specific repeats, Pur repeats I--III, of 64--80 amino acids that are the hallmark of the Pur proteins. Purα has helix-unwinding capability ([@TANAKAMCS000356C21]) and has been shown to bind specific sequences of ssDNA, dsRNA, and ssRNA with preference for GGN-repeats ([@TANAKAMCS000356C7]; [@TANAKAMCS000356C8]; [@TANAKAMCS000356C16]) to regulate a variety of cellular processes including DNA replication, gene transcription, RNA transport, and mRNA translation ([@TANAKAMCS000356C38]; [@TANAKAMCS000356C16]).

Studies on mice have shown that Purα is involved in neuronal proliferation, dendrite maturation, and the transport of mRNA to translation sites in hippocampal neurons ([@TANAKAMCS000356C21]; [@TANAKAMCS000356C17]; [@TANAKAMCS000356C15]; [@TANAKAMCS000356C11]). Two independently generated knockout mouse models demonstrate that mice appear normal at birth but develop neurologic features, including ataxic gait, hind limb weakness, and continuous and increasingly severe tremors ([@TANAKAMCS000356C21]; [@TANAKAMCS000356C11]). The *PURA* knockout mice eat and sleep normally but do not gain weight. Throughout postnatal development, these mice exhibit mislamination of the cerebellum and cerebrum and low numbers of Purkinje cells in the hippocampus and cerebellum associated with uncoordinated movements, tremors, and lethargy with death by 21--25 d. Heterozygous *PURA*^+/−^ mice appeared normal but exhibited neurologic and myeloid defects that were intermediate in severity compared with *PURA*^−/−^ mice. Both *PURA*^−/−^ and *PURA*^+/−^ mice had myeloid defects with reduced splenic monocyte development; however, the effect on *PURA*^+/−^ mice was not as severe as the knockout mice due to *PURA* haploinsufficiency. Heterozygous *PURA*^+/−^ mice also had occasional spontaneous seizures upon handling ([@TANAKAMCS000356C21]; [@TANAKAMCS000356C11]).

In the central nervous system, Purα has been detected in large neuronal mRNA-containing complexes with the fragile X mental retardation protein (FMRP), encoded by *FMR1*, an RNA-binding protein that is required for normal neural development. [@TANAKAMCS000356C15], [@TANAKAMCS000356C16]) showed that Purα is specifically expressed in the dendrites of hippocampal neurons in rats, and colocalizes with FMRP at dendritic junctional translation sites. Purα also binds to CGG repeats in *FMR1*, which is silenced in individuals with fragile X syndrome (FXS) and is overexpressed in patients with fragile X--associated tremor/ataxia syndrome (FXTAS). It is possible that impaired binding of Purα to CGG repeats in FMR1 may play a role in disease progression, resulting in defective neural and brain development in both settings.

Purα is also known to regulate expression of the myelin proteolipid protein Plp1, which is the predominant structural component of myelin sheaths in the central nervous system ([@TANAKAMCS000356C3]). This interaction may be related to the delayed and decreased myelination observed in the brain MRIs. Mutations in *PLP1* are associated with Pelizaeus--Merzbacher disease (PMD; MIM\#312080) ([@TANAKAMCS000356C36]). We hypothesize that abnormal or decreased binding of Purα to its targets may be responsible for defective brain development and function and related to the seizures seen in patients with mutations in *PURA*. Additional studies on patients with *PURA* mutations are necessary to better understand the correlation between genotype and phenotype and further investigation of the molecular mechanism of *PURA* during brain development and function.

METHODS {#s4}
=======

Whole-Exome Sequencing {#s4a}
----------------------

Genomic DNA was extracted from whole blood from 1098 affected children with developmental delay and their parents. Exome sequencing was performed on exon targets isolated by capture using the Agilent SureSelect Human All Exon V4 (50-Mb) kit (Agilent Technologies). One microgram of DNA from blood specimen was sheared into 350--400-bp fragments, which were then repaired, ligated to adaptors, and purified for subsequent PCR amplification. Amplified products were then captured by biotinylated RNA library baits in solution following the manufacturer\'s instructions. Bound DNA was isolated with streptavidin-coated beads and reamplified. The final isolated products were sequenced using the Illumina HiSeq 2000 or 2500 sequencing system with 100-bp paired-end reads (Illumina). DNA sequence was mapped to the published human genome build UCSC hg19/GRCh37 reference sequence using BWA with the latest internally validated version at the time of sequencing, progressing from BWA v0.5.8 through BWA-Mem v0.7.8 ([@TANAKAMCS000356C28]; [@TANAKAMCS000356C27]). Targeted coding exons and splice junctions of known protein-coding RefSeq genes were assessed for average depth of coverage with a minimum depth of 10× required for inclusion in downstream analysis. Local realignment around insertion-deletion sites was performed using the Genome Analysis Toolkit v1.6 ([@TANAKAMCS000356C2]). Variant calls were generated simultaneously on all sequenced family members using SAMtools v0.1.18 ([@TANAKAMCS000356C29]). All coding exons and surrounding intron/exon boundaries were analyzed. Automated filtering removed common sequence changes (defined as \>10% frequency present in 1000 Genomes database). The targeted coding exons and splice junctions of the known protein-coding RefSeq genes were assessed for the average depth of coverage and data quality threshold values. Whole-exome sequence data for all sequenced family members were analyzed using GeneDx\'s XomeAnalyzer (a variant annotation, filtering, and viewing interface for WES data), which includes nucleotide and amino acid annotations, population frequencies (NHLBI Exome Variant Server and 1000 Genomes databases), in silico prediction tools, amino acid conservation scores, and mutation references. Variants were filtered based on inheritance patterns, gene lists of interest, phenotype and population frequencies, as appropriate. Resources including the Human Gene Mutation Database (HGMD), 1000 Genomes database, NHLBI Exome Variant Server, OMIM, PubMed, and ClinVar were used to evaluate genes and detected sequence changes of interest ([Table 3](#TANAKAMCS000356TB3){ref-type="table"}). Additional searches were performed using specific gene lists related to ID. Identified sequence changes of interest were confirmed in all members of the trio by conventional di-deoxy DNA sequence analysis using an ABI3730 (Life Technologies) and standard protocols with a new DNA preparation.

###### 

Variants identified from whole-exome sequencing of six families

                                           Filtering results   Manual review   Resulting genes of interest
  ---------------------------------------- ------------------- --------------- -----------------------------
  Homozygous (\# seq changes)              80 (83)             0 (0)           0 (0)
  Compound heterozygous (\# seq changes)   15 (32)             5 (10)          0 (0)
  De novo (\# seq changes)                 127 (132)           1 (1)           1 (1)
  X-linked genes (\# seq changes)          10 (10)             1 (1)           0 (0)
  Total genes (\# seq changes)             232 (257)           7 (12)          1 (1)
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